Articles published in Current Opinion
in Drug Discovery & Development, Current
Opinion in Molecular Therapeutics, Current
Opinion in Investigational Drugs and IDrugs
are by invitation via the journal Editors based on the recommendations of the
Editorial Board members of these journals. We also welcome proposals, and authors
wishing to submit an article to a relevant journal should contact the Editor
with an outline/abstract, which will be sent to a member of the Editorial Board
for approval. The Current Opinion journals are review-based (we do not publish
primary papers) and all articles are peer reviewed. IDrugs contains feature
articles which highlight and debate topics of current interest in the field.
Preparation of manuscripts
The Editors will provide details of guidelines for authors and a deadline for
submission on approval of the commission.
Proofs
Page proofs will be sent to the corresponding author for final corrections and
approval before publication.
Offprints
Ten offprints will be provided per author free of charge. Additional copies
can be purchased at prices shown on the reprint order form, which is sent with
the page proofs.
Editorial correspondence
- Address all correspondence to:
- Thomson Scientific Commissioning
- Thomson Scientific
- 77 Hatton Garden
- London
- EC1N 8JS
- UK
- TS-EMEA-Commissioning@thomson.com
Points to consider
Is the subject current and of sufficient interest to other people? The article
should be of interest to a range of researchers, and therefore address a subject
of common concern. Of course, you may wish to discuss a new (or neglected) subject
in light of your belief that it will become of greater significance, in which
case please address this in your piece.
It is important that your article looks 'outwards' rather than 'inwards', addressing
researchers in many fields; this is particularly important if your aim in writing
the feature is to persuade readers to your way of thinking. Consider whether
you are writing too much with specialists in mind?
It is easy to fall into jargon, yet one of the aims of the features is to enlighten
qualified, but non-specialist, researchers with developments they may be unaware
of or arguments that they may not have heard before. Has the subject been sufficiently
covered in other recent publications? This follows on from the point above;
although a subject may be of current interest or controversy, it may also be
that there is little remaining to be said.
If writing about such a subject, please consider recent articles when writing
your piece and try to avoid repetition, unless addressing specific points raised
by the said articles.
If addressing a perceived problem, do I have any answers of my own? It is easy
to be critical, less easy to provide alternatives, and we encourage authors
to do so.
